Axon Enterprise (NASDAQ:AXON – Free Report) had its target price hoisted by Northland Securities from $330.00 to $365.00 in a report released on Thursday morning, Benzinga reports. The firm currently has an outperform rating on the biotechnology company’s stock.
Other equities analysts also recently issued reports about the company. Bank of America started coverage on Axon Enterprise in a research report on Wednesday, July 17th. They issued a buy rating and a $380.00 target price on the stock. JMP Securities reissued a market outperform rating and issued a $375.00 target price on shares of Axon Enterprise in a research report on Wednesday. Jefferies Financial Group started coverage on Axon Enterprise in a research report on Wednesday, July 17th. They issued a buy rating and a $385.00 target price on the stock. Morgan Stanley upped their target price on Axon Enterprise from $285.00 to $310.00 and gave the company an equal weight rating in a research report on Friday, April 26th. Finally, Needham & Company LLC reissued a buy rating and issued a $400.00 target price on shares of Axon Enterprise in a research report on Wednesday. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Axon Enterprise presently has a consensus rating of Moderate Buy and a consensus target price of $358.08.
View Our Latest Stock Analysis on AXON
Axon Enterprise Stock Down 0.9 %
NASDAQ:AXON opened at $365.00 on Thursday. The company has a current ratio of 2.91, a quick ratio of 2.55 and a debt-to-equity ratio of 0.37. Axon Enterprise has a twelve month low of $189.12 and a twelve month high of $371.99. The company has a market cap of $27.55 billion, a PE ratio of 106.73, a P/E/G ratio of 6.65 and a beta of 0.95. The company’s 50 day moving average is $300.84 and its two-hundred day moving average is $296.53.
Axon Enterprise (NASDAQ:AXON – Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping the consensus estimate of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.73%. The business had revenue of $504.00 million during the quarter, compared to the consensus estimate of $478.35 million. During the same period in the previous year, the firm posted $0.80 earnings per share. The business’s revenue for the quarter was up 34.5% compared to the same quarter last year. Analysts anticipate that Axon Enterprise will post 2.35 EPS for the current year.
Insider Transactions at Axon Enterprise
In other news, Director Julie A. Cullivan sold 993 shares of the stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $281.72, for a total transaction of $279,747.96. Following the sale, the director now directly owns 4,553 shares of the company’s stock, valued at approximately $1,282,671.16. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, Director Julie A. Cullivan sold 478 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $286.04, for a total value of $136,727.12. Following the transaction, the director now directly owns 5,546 shares of the company’s stock, valued at approximately $1,586,377.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Julie A. Cullivan sold 993 shares of the firm’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $281.72, for a total transaction of $279,747.96. Following the completion of the transaction, the director now directly owns 4,553 shares in the company, valued at $1,282,671.16. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the stock. ICA Group Wealth Management LLC purchased a new position in Axon Enterprise in the 4th quarter valued at about $26,000. Blue Trust Inc. lifted its stake in Axon Enterprise by 987.5% in the 2nd quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 79 shares in the last quarter. Trivant Custom Portfolio Group LLC purchased a new position in Axon Enterprise in the 1st quarter worth approximately $31,000. First PREMIER Bank purchased a new position in Axon Enterprise in the 1st quarter worth approximately $33,000. Finally, Key Financial Inc lifted its stake in Axon Enterprise by 367.6% in the 4th quarter. Key Financial Inc now owns 159 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 125 shares in the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.
About Axon Enterprise
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Featured Articles
Receive News & Ratings for Axon Enterprise Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Axon Enterprise and related companies with MarketBeat.com’s FREE daily email newsletter.
